BioAtla and GATC Health announced a $40 million special purpose vehicle (SPV) to advance ozuriftamab vedotin (Oz‑V, CAB‑ROR2‑ADC) into a Phase 3 registrational study for second‑line and later oropharyngeal squamous cell carcinoma (OPSCC). The financing targets a registrational path for a condition with limited therapeutic options and aims to accelerate enrollment and global regulatory interactions. BioAtla frames Oz‑V as a conditionally active biologic (CAB) ADC directed at ROR2; the SPV structure will fund the Phase 3 while preserving the companies’ balance sheets. Management said the funding shortens timelines to pivotal data and supports broader development plans if efficacy and tolerability are confirmed.